|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
Statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar
|
|
3
|
Tavassoli FA and Devilee P: TNM
classification of carcinomas of the breast. World Health
Classification of Tumours Pathology and Genetics of Tumours of the
Breast and Female Genital Organs. IARC Press; Lyon: pp. 11–12.
2003
|
|
4
|
Rosen PP: Invasive duct carcinoma:
assessment of prognosis, morphologic prognostic markers, and tumor
growth rate. Rosen’s Breast Pathology. 3rd edition. Lippincott
Williams & Wilkins; Philadelphia, PA: pp. 358–404. 2009
|
|
5
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldhirsch A, Wood WC, Coates AS, et al:
Panel members: Strategies for subtypes - dealing with the diversity
of breast cancer: highlights of the St. Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann
Oncology. 22:1736–1747. 2011. View Article : Google Scholar
|
|
7
|
Carey L, Perou CM, Livasy CA, et al: Race,
breast cancer subtypes and survival in the Carolina Breast Cancer
Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mullan PB and Millikan RC: Molecular
subtyping of breast cancer: opportunities for new therapeutic
approaches. Cell Mol Life Sci. 64:3219–3232. 2007.PubMed/NCBI
|
|
9
|
Dowsett M, Nielsen OT, A’Hern R, et al;
International Ki-67 in Breast Cancer Working Group. Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664.
2011. View Article : Google Scholar
|
|
10
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldhirsch A, Ingle JN, Gelber RD, et al:
Panel members: Thresholds for therapies: highlights of the St
Gallen International Expert Consensus on the primary therapy of
early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar
|
|
12
|
Yerushalmi R, Woods R, Ravdin PM, et al:
Ki67 in breast cancer: prognostic and predictive potential. Lancet
Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varga Z, Diebold J, Dommann-Scherrer C, et
al: How reliable is Ki-67 immunohistochemistry in grade 2 breast
carcinomas? A QA study of the Swiss Working Group of Breast- and
Gynecopathologists. PLoS One. 7:e373792012. View Article : Google Scholar
|
|
14
|
Fitzgibbons PL, Page DL, Weaver D, et al:
Prognostic factors in breast cancer. College of American
Pathologists Consensus Statement 1999. Arch Pathol Lab Med.
124:966–978. 2000.PubMed/NCBI
|
|
15
|
Edge SB, Byrd DR, Compton CC, et al:
Breast. AJCC Cancer Staging Manual. 7th edition. Springer; New
York, NY: pp. 345–376. 2010
|
|
16
|
Derek AC: Breast carcinoma. Histopathology
Reporting Guidelines for Surgical Cancer. Springer-Verlag; London:
pp. 213–235. 2006
|
|
17
|
Moinfair F: Infiltrating ductal carcinoma
(NOS type). Essentials of Diagnostic Breast Pathology. A Practical
Approach. Springer; Berlin Heidelberg, New York, NY: pp. 180–181.
2007
|
|
18
|
Rakha EA, Reis-Filho JS, Baehner F, et al:
Breast cancer prognostic classification in the molecular era: the
role of histological grade. Breast Cancer Res.
12:2072010.PubMed/NCBI
|
|
19
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
20
|
Dunne B and Going JJ: Scoring nuclear
pleomorphism in breast cancer. Histopathology. 39:259–265. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elston CW and Ellis IO: Assessment of
histological gradee. Systemic Pathology. The Breast. 13. 3rd
edition. Churchill Livingstone; Philadelphia, PA: pp. 365–384.
1998
|
|
22
|
Rampaul RS, Pinder SE, Elston CW and Ellis
IO; Nottingham Breast Team. Prognostic and predictive factors in
primary breast cancer and their role in patient management: The
Nottingham Breast Team. Eur J Surg Oncol. 27:229–238. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wolff AC, Hammond HE, Schwartz JN, et al;
American Society of Clinical Oncology; College of American
Pathologists. American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar
|
|
24
|
Rakha EA, Elsheikh SE, Aleskandarany MA,
et al: Triple-negative breast cancer: distinguishing between basal
and nonbasal subtypes. Clin Cancer Res. 15:2302–2310. 2009.
View Article : Google Scholar
|
|
25
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
31:13–20. 1983. View Article : Google Scholar
|
|
26
|
Beresford MJ, Wilson GD and Makris A:
Measuring proliferation in breast cancer: practicalities and
applications. Breast Cancer Res. 8:2162006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerdes J, Li L, Schlueter C, et al:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873. 1991.
|
|
28
|
du Manoir S, Guillaud P, Camus E, et al:
Ki-67 labeling in postmitotic cells defines different Ki-67
pathways within the 2c compartment. Cytometry. 12:455–463.
1991.PubMed/NCBI
|
|
29
|
Bruno S and Darzynkiewicz Z: Cell cycle
dependent expression and stability of the nuclear protein detected
by Ki-67 antibody in HL-60 cells. Cell Prolif. 25:31–40. 1992.
View Article : Google Scholar
|
|
30
|
Gerdes J, Lemke H, Baisch H, et al: Cell
cycle analysis of a cell proliferation-associated human nuclear
antigen defined by the monoclonal antibody Ki-67. J Immunol.
133:1710–1715. 1984.
|
|
31
|
Park D, Kåresen R, Noren T and Sauer T:
Ki-67 expression in primary breast carcinomas and their axillary
lymph node metastases: clinical implications. Virchows Arch.
451:11–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aleskandarany MA, Green AR, Benhasouna AA,
et al: Prognostic value of proliferation assay in the luminal,
HER2-positive and triple-negative biologic classes of breast
cancer. Breast Cancer Res. 14:R32012. View Article : Google Scholar
|
|
33
|
Luporsi E, André F, Spyratos F, et al:
Ki-67: level of evidence and methodological considerations for its
role in the clinical management of breast cancer: analytical and
critical review. Breast Cancer Res Treat. 132:895–915. 2012.
View Article : Google Scholar
|
|
34
|
Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
|
|
35
|
Yamaguchi T and Mukai H: Ki-67 index
guided selection of preoperative chemotherapy for HER2-positive
breast cancer: a randomized phase II trial. Jpn J Clin Oncol.
42:1211–1214. 2012. View Article : Google Scholar
|
|
36
|
Jalava P, Kuopio T, Juntti-Patinen L, et
al: Ki67 immunohistochemistry: a valuable marker in prognostication
but with a risk of misclassification: proliferation subgroups
formed based on Ki67 immunoreactivity and standardized mitotic
index. Histopathology. 48:674–682. 2006. View Article : Google Scholar
|
|
37
|
Arber DA: Effect of prolonged formalin
fixation on the immunohistochemical reactivity of breast markers.
Appl Immunohistochem Mol Morphol. 10:183–186. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Camp RL, Charette LA and Rimm DL:
Validation of tissue microarray technology in breast carcinoma. Lab
Invest. 80:1943–1949. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
DiVito KA, Charette LA, Rimm DL and Camp
RL: Long-term preservation of antigenicity on tissue microarrays.
Lab Invest. 84:1071–1078. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Boon ME: Microwave-antigen retrieval: the
importance of pH of the retrieval solution for MIB-1 staining. Eur
J Morphol. 34:375–379. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mengel M, von Wasielewski R, Wiese B, et
al: Inter-laboratory and inter-observer reproducibility of
immunohistochemical assessment of the Ki-67 labelling index in a
large multi-centre trial. J Pathol. 198:292–299. 2002. View Article : Google Scholar
|
|
42
|
Faratian D, Munro A, Twelves C and
Bartlett JM: Membranous and cytoplasmic staining of Ki67 is
associated with HER2 and ER status in invasive breast carcinoma.
Histopathology. 54:254–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tawfik O, Kimler BF, Davis M, et al:
Grading invasive ductal carcinoma of the breast: advantages of
using automated proliferation index instead of mitotic count.
Virchows Arch. 450:627–636. 2007. View Article : Google Scholar
|
|
44
|
Viale G, Giobbie-Hurder A, Regan MM, et
al; Breast International Group Trial 1-98. Prognostic and
predictive value of centrally reviewed Ki-67 labeling index in
postmenopausal women with endocrine-responsive breast cancer:
results from Breast International Group Trial 1-98 comparing
adjuvant tamoxifen with letrozole. J Clin Oncol. 26:5569–5575.
2008. View Article : Google Scholar
|
|
45
|
Mohammed ZM, McMillan DC, Elsberger B, et
al: Comparison of visual and automated assessment of Ki-67
proliferative activity and their impact on outcome in primary
operable invasive ductal breast cancer. Br J Cancer. 106:383–388.
2012. View Article : Google Scholar
|
